KVUE Kenvue Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel ceiling · 18-month channel going sideways
Price is at the upper line, where it has stalled before.
- 18-month channel
- US$17.72 – US$19.21 · going sideways, −1% a year
- Price in channel
- 109% (0% = floor, 100% = ceiling)
- Ceiling overhead
- none — above both ceilings
- Turns bearish below
- US$17.72
Price history, with the path projected 3 months forward
Updated 2:59 PM ET (45 h ago)
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: no target size has paid on this stock’s own record, so there is none to publish Levels below are for reference only.
Buy at or below
US$17.72
level as at 1 Nov 2026
Our target
US$19.21
by 2 Nov 2026
Projected move
8.4%
gross, before costs
Price is at or past our target.
- Upper line touches
- 4
- Lower line touches
- 5
- Fit confidence
- 57%
- Fitted
- 1 Nov 2026
Company information
About Kenvue Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry
- Employees
- 21,890
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$34.14B
- Enterprise value
- —
- Beta
- 0.43
- Avg volume
- 20.78M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 14.02-20.13
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.